The ECOG-ACRIN Cancer Research Group’s Central Biorepository and Pathology Facility, located at The University of Texas MD Anderson Cancer Center in Houston, provides and coordinates services to collect, process, store, catalog, ensure quality control, and distribute biospecimens with annotated clinical and molecular data. Biospecimens are obtained from patients enrolled in clinical trials that are developed across ECOG-ACRIN’s three scientific programs: Cancer Control and Outcomes, Therapeutic Studies, and Biomarker Sciences.
In addition to these fundamental banking activities, the Central Biorepository and Pathology Facility supports translational and clinical research, including regulatory-grade assays for integral biomarkers, across the National Cancer Institute’s National Clinical Trials Network, the National Cancer Institute Community Oncology Research Program, and the broader cancer research community. While the routine procurement, processing, and distribution of patient materials remain its core functions, the facility continually incorporates advanced processes, including, but not limited to, new technology platforms that allow for high-throughput pre-analytic and analytic procedures.
The facility recognizes its responsibility as a custodian of the patients’ materials, and places patient care and privacy above all other issues. It aims to be an independent, centralized specimen repository and pathology facility to serve ECOG-ACRIN investigators, the National Cancer Institute, and the cancer research community, especially the patients who consent to participate in clinical trials.
Facility Collects, Processes, and Stores Wide Spectrum of High-Quality Biospecimens